BeiGene-283: Phase Ib started

BeiGene began an open-label, Australian and New Zealand Phase Ib trial to evaluate once-daily oral BGB-283 in patients with solid tumors that harbor BRAF mutations and/or aberrations in the RAS-mitoge...